COVID-19 (Coronavirus)

Rostock International Parkinson's Disease Study

Condition: Parkinson's disease

Eligibility

Key Inclusion Criteria:

  • Diagnosed with Parkinson‘s disease (PD), or is a family member of a participant with LRRK2 parkinsonism, or is a member of a high-risk population with an early PD onset
  • At least 18 years old

Key Exclusion Criteria:

  • Unable to provide informed consent
  • Previously enrolled in the study
     

Full Study Name:

Rostock International Parkinson's Disease Study (ROPAD) (IRB no. 00000519)

Summary

Parkinson’s disease (PD) is one of the most common neurological disorders worldwide. Previous studies suggest that PD has important genetic factors contributing to the development of the disease. Approximately 15% of PD patients report a family history of disease, including some who have a form of the disease that is based on the functional defect of a single gene. The most frequent known cause for PD are mutations in the LRRK2 (leucine-rich repeat kinase 2 gene) and in the glucocerebrosidase genes.

The purpose of this study is to identify LRRK2-positive PD patients, as well as 1,500 non-LRRK2 PD patients. Participants’ medical history and blood samples will be evaluated, and a brief neurological examination will be performed. Researchers also aim to establish a LRRK2-positive biomarker in the LRRK2-positive group of patients. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that may be a sign of a condition or disease.

Principal Investigator
Contact